Biocryst Pharmaceuticals (BCRX) Change in Cash (2010 - 2026)

Biocryst Pharmaceuticals' Change in Cash history runs 17 years deep, the most recent figure standing at $82.0 million for Q1 2026.

• Quarterly Change in Cash rose 14602.69% year-over-year to $82.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.5 million (up 220.47% YoY) and the FY2025 annual result came in at -$15.0 million, down 144.71% from the prior year.
• Change in Cash was $82.0 million for Q1 2026 at Biocryst Pharmaceuticals, up from -$9.6 million in the prior quarter.
• Across five years, Change in Cash topped out at $82.0 million in Q1 2026 and bottomed at -$149.6 million in Q1 2023.
• A 5-year average of -$19.7 million and a median of -$5.9 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash sank 668.33% — and 2026, when it jumped 14602.69%.
• Biocryst Pharmaceuticals' Change in Cash stood at $57.9 million in 2022, then plunged by 169.16% to -$40.0 million in 2023, then soared by 118.13% to $7.3 million in 2024, then plunged by 231.7% to -$9.6 million in 2025, then soared by 958.17% to $82.0 million in 2026.
• Business Quant data shows BCRX's Change in Cash at $82.0 million in Q1 2026, -$9.6 million in Q4 2025, and -$4.1 million in Q3 2025.